Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

More manufacturers are contributing their analytical data to an excipient database to pool knowledge on the risk posed by excipients that may cause drugs to exceed acceptable PDE levels under ICH Q3D.

South Korea’s Boryung Pharm has now signed $1 billion worth of global agreements for its antihypertensive Kanarb, while U.S. regenerative medicine company Orgenesis, which is working to cure type 1 diabetes with technology that combines cellular and regenerative therapy, has signed collaborative deals with two Korean partners, a recent meeting in Seoul heard.

A highly fragmented market, low penetration and a proactive regulatory environment could help Indian drug firms make a serious bid for the Latin American market.